🏛️ Verified NIH Record • Updated 2026-06-01
Atrasentan in Patients With IgA Nephropathy (NCT04573478)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals
🩺 Plain-English Summary (8th-Grade Level)
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (135 Sites)
Showing the first 25 of 135 sites.
- University of Alabama at Birmingham — Birmingham, Alabama
- Comprehensive Research Institute — Alhambra, California
- Kidney Disease Medical Group — Glendale, California
- Stanford University — Stanford, California
- University of Florida — Gainesville, Florida
- GA Nephrology Associates — Lawrenceville, Georgia
- NANI Research, LLC — Hinsdale, Illinois
- NANI Research, LLC — Fort Wayne, Indiana
- University of Louisville Physicians- Kidney Disease Program — Louisville, Kentucky
- Tufts Medical Center — Boston, Massachusetts
- Intermed Consultants — Minneapolis, Minnesota
- Pelican Point Dialysis - DaVita Clinical Research — Las Vegas, Nevada
- Capital District Renal Physicians — Clifton Park, New York
- Mountain Kidney and Hypertension Associates — Asheville, North Carolina
- Brookview Hills Research Associates, LLC — Winston-Salem, North Carolina
- Lehigh Valley Hospital — Bethlehem, Pennsylvania
- University of Pennsylvania — Philadelphia, Pennsylvania
- Liberty Research Center — Dallas, Texas
- El Paso Kidney Specialists — El Paso, Texas
- Nephrology Associates Of Northern Virginia — Fairfax, Virginia
- Swedish Health Services — Seattle, Washington
- Centro Médico Ce.Re.Ca — San Luis, San Luis Province
- CEMIC — Buenos Aires,
- Hospital Britanico de Buenos Aires — Buenos Aires,
- Clinica de Nefrologia Urologia y Enf. Cardiovasculares — Santa Fe,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in IgA Nephropathy
- A Study of Zigakibart in Adults With IgA Nephropathy — Birmingham, Alabama
- Atrasentan in Patients With Proteinuric Glomerular Diseases — Glendale, California
- Atacicept in Subjects With IgA Nephropathy — Brisbane, California
- A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G — Lawrenceville, Georgia
- Study of BHV-1400 in IgA Nephropathy — Farmington, Connecticut
Explore by condition: All IgA Nephropathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.